Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS

Inclusion Criteria

• •Age up to 18 years old
• •With a diagnosis formally established of DLBCL or transformed straightaway follicular lymphoma or 3B grade follicular lymphoma or Burkitt-like lymphoma
• •Eligible to a treatment by immunochemotherapy like R-CHOP, R-ACVBP or R-CHOP like
• •First line of treatment
• •Being able to benefit from standard extension assessment ( Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and bone marrow biopsy with a bone marrow aspiration)
• •Written informed consent
• •Tumor biopsy used for diagnosis available